Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7904346 | 1.00 | CYP1A2 (0.52) | CYP1A2TDP1HSD17B10HTR1ANPC1 | |
| SCHEMBL17708305 | 1.00 | CYP1A2 (0.52) | CYP1A2TDP1HSD17B10HTR1ANPC1 | |
| SCHEMBL16906761 | 0.92 | HTT (0.50) | CYP1A2TDP1HSD17B10HTR1ANPC1 | |
| SCHEMBL13324885 | 0.90 | MEN1 (0.41) | CYP1A2TDP1HSD17B10HTR1ANPC1 | |
| SCHEMBL188546 | 0.83 | CYP1A2 (0.54) | CYP1A2TDP1HSD17B10HTR1ANPC1 | |
| SCHEMBL18389800 | 0.82 | CYP1A2 (0.48) | CYP1A2TDP1HSD17B10HTR1ANPC1 | |
| SCHEMBL3288873 | 0.80 | MMP1 (0.44) | TP53ALDH1A1HPGDHTT | |
| SCHEMBL3298525 | 0.80 | MMP1 (0.44) | TP53ALDH1A1HPGDHTT | |
| SCHEMBL1417346 | 0.80 | MMP1 (0.44) | TP53ALDH1A1HPGDHTT | |
| SCHEMBL24302109 | 0.79 | CYP1A2 (0.50) | CYP1A2TDP1HSD17B10HTR1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440981-B2 | Pyrrolo[2, 1-F] [1,2,4]triazine derivative and use thereof for treating tumors | PHARMABLOCK (NANJING) R&D CO. LTD (CN) | 2016-09-13 | — | — | US | disclosed |
| US-9440981-B2 | Pyrrolo[2, 1-F] [1,2,4]triazine derivative and use thereof for treating tumors | PHARMABLOCK (NANJING) R&D CO. LTD (CN) | 2016-09-13 | — | — | US | disclosed |
| US-20160115166-A1 | PYRROLO[2, 1-F] [1,2,4]TRIAZINE DERIVATIVE AND USE THEREOF FOR TREATING TUMORS | PHARMABLOCK (NANJING) R&D CO. LTD. (CN) | 2016-04-28 | — | — | US | disclosed |
| US-20160115166-A1 | PYRROLO[2, 1-F] [1,2,4]TRIAZINE DERIVATIVE AND USE THEREOF FOR TREATING TUMORS | PHARMABLOCK (NANJING) R&D CO. LTD. (CN) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115166-A1 | PYRROLO[2, 1-F] [1,2,4]TRIAZINE DERIVATIVE AND USE THEREOF FOR TREATING TUMORS | GLS2, GTF2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP1A2 249/4885TDP1 2255/4885HSD17B10 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.